Opinion|Videos|December 9, 2024
Addressing the Psychosocial Impact of Vitiligo: Enhancing Patient Support and Treatment Adherence
Author(s)Seemal Desai, MD, FAAD
The panelist discusses how vitiligo’s psychological and social impacts significantly affect patients’ quality of life and treatment adherence, necessitating a holistic approach that addresses both physical symptoms and psychosocial support needs.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do the psychological and social impacts of vitiligo affect your patients?
- How do you address these issues?
- In your experience, what role do psychosocial impacts play in treatment adherence?
Advertisement
Related to this article
Dan Nardi shares how Reimagine Care uses AI triage and connected devices to scale outpatient cancer support, enabling faster, personalized symptom monitoring.
In this interview, Jordan Herring, Ph.D., and Carlos E. Rodriguez-Diaz, Ph.D., MPHE, MCHES, discuss their study, which found a 16.8% increase in HIV incidence rates among Hispanic populations in antisanctuary counties after 2018 immigration policy shifts.
Metabolic dysfunction-associated steatotic liver disease (MASLD) may differ biologically from obesity-linked MASH, a mouse study suggests, with salt driving liver inflammation without obesity.
In this discussion, Ohio State economist Eric Seiber, Ph.D., explains how inconsistent claims-data definitions can skew estimates of first-episode psychosis and why standardization matters for early treatment and sustainable payment models.
CMS’ mandatory GLOBE drug model ties some Medicare Part B rebates to global prices, but cuts projected savings sharply amid shifting Part D premiums.
Bill Kerr of Avalon Heath Solutions says incorporating Z codes into CPT codes for lab and genetic testing would add needed specificity, reduce waste and possibly head off fraud.
States have to turn that information into medical frailty determinations that are clinically credible, consistent, and workable across large Medicaid populations.
A meta-analysis found steatotic liver disease in 75% of patients with sleep-disordered breathing and that CPAP lowered liver enzymes but not liver fat.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Closing the outpatient monitoring gap in cancer
2
A conversation with Jordan Herring, Ph.D., and Carlos E. Rodriguez-Diaz, Ph.D., MPHE, MCHES, about the relationship between HIV incidence in Hispanic communities and immigration policy
3
Final GLOBE drug model projects much smaller savings while 2027 Part D premiums split
4
FAQ: State PBM reform in 2026—What's new since spring
5